Article

Deciphering the mechanism underlying late-onset Alzheimer disease

Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Nature Reviews Neurology (Impact Factor: 15.36). 11/2012; 9(1). DOI: 10.1038/nrneurol.2012.236
Source: PubMed

ABSTRACT

Despite tremendous investments in understanding the complex molecular mechanisms underlying Alzheimer disease (AD), recent clinical trials have failed to show efficacy. A potential problem underlying these failures is the assumption that the molecular mechanism mediating the genetically determined form of the disease is identical to the one resulting in late-onset AD. Here, we integrate experimental evidence outside the 'spotlight' of the genetic drivers of amyloid-β (Aβ) generation published during the past two decades, and present a mechanistic explanation for the pathophysiological changes that characterize late-onset AD. We propose that chronic inflammatory conditions cause dysregulation of mechanisms to clear misfolded or damaged neuronal proteins that accumulate with age, and concomitantly lead to tau-associated impairments of axonal integrity and transport. Such changes have several neuropathological consequences: focal accumulation of mitochondria, resulting in metabolic impairments; induction of axonal swelling and leakage, followed by destabilization of synaptic contacts; deposition of amyloid precursor protein in swollen neurites, and generation of aggregation-prone peptides; further tau hyperphosphorylation, ultimately resulting in neurofibrillary tangle formation and neuronal death. The proposed sequence of events provides a link between Aβ and tau-related neuropathology, and underscores the concept that degenerating neurites represent a cause rather than a consequence of Aβ accumulation in late-onset AD.

Download full-text

Full-text

Available from: Irene Knuesel
  • Source
    • "Supportive of this model, APP expression in the brain of DS is significantly higher than predicted by the gene triplication suggesting that other factors could turn on this gene expression. Cytokines and LPS are candidates as they were found to consistently stimulate amyloid synthesis and induce cognitive impairment [7]. Our own studies showed that in NL subjects, measures of history of PerioD associated with amyloid accumulation in the brain [58] and affect tau protein hyperphos- phorylation [36]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: People with Down syndrome (DS) are at an increased risk for Alzheimer's disease (AD). After 60 years of age, >50% of DS subjects acquire dementia. Nevertheless, the age of onset is highly variable possibly because of both genetic and environmental factors. Genetics cannot be modified, but environmental risk factors present a potentially relevant intervention for DS persons at risk for AD. Among them, inflammation, important in AD of DS type, is potential target. Consistent with this hypothesis, chronic peripheral inflammation and infections may contribute to AD pathogenesis in DS. People with DS have an aggressive form of periodontitis characterized by rapid progression, significant bacterial and inflammatory burden, and an onset as early as 6 years of age. This review offers a hypothetical mechanistic link between periodontitis and AD in the DS population. Because periodontitis is a treatable condition, it may be a readily modifiable risk factor for AD.
    Full-text · Article · Feb 2016
  • Source
    • "However, these mutations are rare but predispose the individual to developing early-onset AD, which accounts for approximately 3% of all cases of AD. The sporadic and most common form, late-onset Alzheimer's disease (LOAD)[13,14], is also likely to have a complex pattern of genetic inheritance that has to date eluded detection. It is known that the presence of one or two copies of the ε4 allele in the apolipoprotein E gene (APOE, chromosome 19q13.2) increases an individual's susceptibility to LOAD[15]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Alzheimer's disease (AD) is a complex, multifactorial disease that has reached global epidemic proportions. The challenge remains to fully identify its underlying molecular mechanisms that will enable development of accurate diagnostic tools and therapeutics. Conventional experimental approaches that target individual or small sets of genes or proteins may overlook important parts of the regulatory network, which limits the opportunity of identifying multitarget interventions. Our perspective is that a more complete insight into potential treatment options for AD will only be made possible through studying the disease as a system. We propose an integrative systems biology approach that we argue has been largely untapped in AD research. We present key publications to demonstrate the value of this approach and discuss the potential to intensify research efforts in AD through transdisciplinary collaboration. We highlight challenges and opportunities for significant breakthroughs that could be made if a systems biology approach is fully exploited.
    Full-text · Article · Dec 2015 · Alzheimer's and Dementia
  • Source
    • "At present, plenty of new data from biomedical research reveals the need to revise current ideas about AD origins. It has been proposed that primary pathological changes, preceding A␤ overproduction and tau pathology, appear in neurons in response to the first hit of damaging factors (reviewed in [13] [14] [15] [16] [17] [18]). Such early pathological changes in AD include calcium dyshomeostasis , mitochondria impairment, an increase in the oxidative stress level, and abnormalities in cell cycle regulation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In Alzheimer's disease (AD), molecular changes are observed not only in patients' neurons but also in peripheral cells, such as blood lymphocytes. These include changes in the level of oxidative stress markers, mitochondria impairment, and aberrant cell cycle regulation in AD blood lymphocytes. While the concepts of early causes of AD are currently highly controversial, these findings provide support for the cell cycle hypothesis of AD pathomechanism and emphasize the systemic nature of the disease. Moreover, because of difficulties in studying dynamic processes in the human brain, lymphocytes seem to be useful for readout of AD molecular mechanisms. In addition, lymphocytes as easily accessible human cells have potential diagnostic value. We summarize current perspectives for the development of new therapeutic strategies based on oxidative stress and cell cycle dysregulation in AD, and for diagnostic methodologies involving new markers in AD lymphocytes.
    Full-text · Article · Mar 2015 · Journal of Alzheimer's disease: JAD
Show more